Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which constitutively activates the tropomyosin‐related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity i...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pediatric blood & cancer Ročník 65; číslo 10; s. e27271 - n/a
Hlavní autori:	Halalsheh, Hadeel, McCarville, Mary Beth, Neel, Michael, Reynolds, Mark, Cox, Michael C., Pappo, Alberto S.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Wiley Subscription Services, Inc 01.10.2018
Predmet:	bone metastasis Bone remodeling ETV6–NTRK Hematology Infants larotrectinib mesoplastic nephroma Metastases Neonates Oncology Pediatrics Signal transduction TRK inhibitor Tropomyosin mesoplastic nephroma larotrectinib bone metastasis ETV6-NTRK TRK inhibitor
ISSN:	1545-5009, 1545-5017, 1545-5017
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!